Despite these potential differences, it is important to note that the integrated analysis of entrectinib remains the most relevant dataset for comparison of the results of BFAST Cohort D, because it is the only other analysis of patients with ROS1-positive, advanced/metastatic NSCLC who have been treated with entrectinib. Here, ROS1 is linked to non-small cell lung carcinoma.